Transpek Industry Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company is focused on cash conservation, cost optimization, and improving cash flow, which has helped reduce borrowing costs from around 8% to about 6.2%. - Capex plans are currently on hold due to government restrictions and market conditions; the company is exploring opportunities but has not indicated any immediate significant capital raising. - Expansion is constrained due to regulatory permissions, and the company relies on job work facilities to meet capacity needs. - Management stated that any future capex will be announced once significant opportunities arise, implying potential future funding needs but no concrete plans now.

- Current status: The previously announced new capex project has been put on hold due to COVID-19; ongoing capex is primarily for replacement and upgradation. - Future plans: Capex for the next two years will focus on introduction of new products, announced as significant investments materialize. - Capacity utilization is being enhanced through three job work sites (about 12,000 MT capacity) due to government restrictions on expansion at the main plant. - The company is exploring product mix changes at job work sites without requiring new environmental clearances. - Expansion is currently restricted by government permissions; the company is working with government and industry associations for enabling future capacity expansions. - No immediate significant capex expected until new opportunities arise; strategy is to balance product portfolio and derisk with new applications in pharma, agro, and electronics. - Long-term capex decisions are linked to market demand and customer validations of new products.

- Growth will take time due to product validation and customer approvals, especially for new pharma and agrochemical products. - Sequential growth expected as new products are introduced and validated; some customers are already ready though volumes are not significant yet. - Current strategy focuses on derisking by broadening product mix across applications like pharma, agro, electronics, beyond polymers. - Polymer application currently ~70% of sales; expected to reduce to 45%-50% over 2-2.5 years with increased contribution from other segments. - Capacity utilization improving (currently ~65%), but overall volumes are impacted by sectors like aerospace and automotive recovering slowly. - Long-term growth tied to new product introductions, with capex dependent on market opportunities; large capex paused due to COVID but may resume when justified. - Take-or-pay contracts provide some revenue stability even at lower volumes. - Overall, normal revenue range expected between Rs. 500-700 Crores with EBITDA in 16%-20% range as markets normalize.

- EBITDA margin expected in the range of 16% to 20% going forward, reflecting normalized performance (Page 7). - Revenue normalization anticipated between Rs. 500 Crores to Rs. 700 Crores as aerospace and automotive sectors recover (Page 8). - Capacity utilization recovery noted, reaching about 65% currently from 35% earlier, signaling better operational performance ahead (Page 16-17). - Growth strategy includes broadening product portfolio beyond polymers into pharma, agrochemicals, electronics, etc., aiming to reduce concentration risk from 70% polymer revenue to about 45-50% over 2-2.5 years (Pages 10-12). - New product introductions expected but involve validation and will take 2-2.5 years to scale; initial readiness with some pilot approvals underway (Pages 10-12). - Capex will align with new opportunities; major capex on hold until better clarity on market recovery (Page 4, 12). - Take-or-pay contract ensures minimum revenue compensation, supporting stable cash flows despite volume dips (Page 9). - Overall, gradual improvement in earnings expected as markets normalize and new products commercialize.

- Current order volumes are low but supplies under contract are continuing steadily every month; no indication of force majeure or contract disruption. - The company expects about Rs.150 Crores to Rs.200 Crores additional revenue potential from three job work sites as orders recover. - Discussions are ongoing with customers for long-term contracts, including a two-year contract with another customer. - The company is in continuous contact with customers to gauge order flow; however, visibility remains uncertain due to external factors like the pandemic. - No major backlog or pending orderbook explicitly quantified, but management is poised to capture growth momentum as demand improves. - Contract includes take-or-pay arrangements providing compensation mechanisms even if minimum volumes are not met.